STOCK TITAN

NextPlat Q3 2026 loss narrows to $748K as revenue falls

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

NextPlat Corp (NXPL) reported third-quarter 2026 revenue of $10.499 million, down from $13.752 million a year earlier. Gross profit increased to $3.678 million from $2.730 million, a nearly 35% rise, while consolidated gross margin was 35.0% versus 19.9%. Net loss attributable to common stockholders narrowed approximately 66% to $748,000, or a loss of $0.28 per diluted share, from $2.185 million, or a loss of $0.84 per diluted share.

Healthcare pharmacy contract revenue increased 300% to approximately $2.4 million from $0.6 million, while pharmacy prescription revenue was approximately $4.3 million versus $9.5 million. Healthcare gross margin was approximately 41%, compared with 18%, and e-commerce revenue rose 3% to approximately $3.8 million. 340B prescription volumes grew nearly 72% year over year. The company added three 340B services contracts; onboarding is underway and is expected to contribute revenue in early 2027.

As of September 30, 2026, cash was $11.220 million and working capital was approximately $13.5 million; the company reported no material unsecured debt. It completed the Scott’s pharmacy acquisition immediately after quarter-end and announced a Jacksonville location. A nationwide medication-fulfillment website is on track to launch in the fourth quarter of 2026.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointGross profit rose nearly 35% year over year.
  • Moderate pointNet loss narrowed approximately 66% to $748,000.
  • Moderate pointConsolidated gross margin reached 35.0%, versus 19.9%.

Negative

  • Moderate pointRevenue fell to $10.499 million from $13.752 million.

Filing Explained

Cash was lower at September 30, 2026 than at December 31, 2025.

The November 12, 2026 Form 8-K furnishes NextPlat's third-quarter results; its balance sheet shows 2,708,475 common shares outstanding on September 30, 2026, versus 2,663,734 on December 31, 2025, so the higher share count means existing holders own a smaller percentage absent offsetting changes.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $10.499 million Three months ended September 30, 2026; $13.752 million in the comparable 2025 period.
Gross profit $3.678 million Three months ended September 30, 2026; $2.730 million in the comparable 2025 period.
Consolidated gross margin 35.0% Third quarter 2026, compared with 19.9% in the third quarter of 2025.
Net loss attributable to common stockholders $748,000 loss Three months ended September 30, 2026; $2.185 million loss in the comparable 2025 period.
Loss per diluted share $0.28 loss Third quarter 2026; $0.84 loss in the third quarter of 2025.
Pharmacy contract revenue Approximately $2.4 million Third quarter 2026; approximately $0.6 million in the prior-year period, an increase of 300%.
340B prescription volume Nearly 72% year-over-year growth Third quarter 2026.
Cash $11.220 million As of September 30, 2026.
340B medical
"growth in 340B contract revenue"
340B is a U.S. federal program that lets qualifying hospitals and clinics buy outpatient prescription drugs at steep, government-negotiated discounts so they can stretch limited budgets and serve low-income or uninsured patients. For investors, 340B affects how much drugmakers earn on certain sales and how safety-net providers generate margin—think of it like a factory discount card that changes both the seller’s revenue and the buyer’s ability to reinvest savings in operations.
gross margin financial
"Overall gross margin ... approximately 35.0%"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
medication fulfillment medical
"medication fulfillment contract services"
reimbursement rates financial
"lower reimbursement rates"
working capital financial
"working capital of approximately $13.5 million"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
airtime services technical
"record high-margin, recurring airtime contract revenue"
Revenue $10.499 million Down from $13.752 million in the comparable 2025 period
Gross profit $3.678 million Up from $2.730 million; the company described the year-over-year improvement as nearly 35%
Consolidated gross margin 35.0% Compared with 19.9% in the third quarter of 2025
Net loss attributable to common stockholders $748,000 loss Narrowed approximately 66% from a $2.185 million loss
Loss per diluted share $0.28 loss Compared with a $0.84 loss in the third quarter of 2025
Pharmacy contract revenue Approximately $2.4 million Increased 300% from approximately $0.6 million
340B prescription volumes Nearly 72% year-over-year growth Third quarter 2026
Cash $11.220 million As of September 30, 2026
Guidance

The company expects retail prescription volumes to increase starting in the fourth quarter of 2026 and said its nationwide medication-fulfillment website is on track to launch during the fourth quarter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did NXPL report in Q3 2026?

NextPlat reported $10.499 million in third-quarter 2026 revenue, compared with $13.752 million in the third quarter of 2025. The company attributed the lower revenue largely to lower reimbursement rates and lower retail prescription volumes in its Healthcare operations.

How did NXPL’s Q3 2026 gross margin and net loss compare?

Consolidated gross margin was 35.0%, compared with 19.9% a year earlier. Net loss attributable to common stockholders narrowed approximately 66% to $748,000, or a loss of $0.28 per diluted share, from $2.185 million, or a loss of $0.84 per diluted share.

What did NXPL report about 340B growth and new contracts?

340B prescription volumes grew nearly 72% year over year, and NextPlat added three 340B services contracts during the quarter. Onboarding is underway, and the company expects the new contracts to contribute revenue in early 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001058307 0001058307 2026-11-12 2026-11-12 0001058307 nxpl:CommonStockCustomMember 2026-11-12 2026-11-12
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 12, 2026
 
NEXTPLAT CORP
(Exact Name of Registrant as Specified in its Charter)
 
Nevada
 
001-40447
 
65-0783722
(State or Other Jurisdiction
of Incorporation or Organization)
 
(Commission
File No.)
 
(I.R.S. Employer
Identification No.)
 
400 Ansin Blvd, Suite A
Hallandale Beach, FL 33009
(Address of principal executive offices and zip code)
 
(305) 560-5381
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed from last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol (s)
 
Name of each exchange on which registered
Common Stock, par value $0.0001
 
NXPL
 
The Nasdaq Stock Market LLC
 


 
 

 
Item 2.02. Results of Operations and Financial Condition
 
On November 12, 2026, NextPlat Corp (the “Registrant”) issued a press release announcing certain financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
 
Item 9.01. Financial Statements and Exhibits.
 
Exhibits.
 
Exhibit No.
 
Description
99.1
 
Press Release
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NEXTPLAT CORP.
     
 
By:
/s/ David Phipps
 
Name:
David Phipps
 
Title:
Chief Executive Officer and President
     
Dated: November 13, 2026
   
 
 

Exhibit 99.1

nextplat_new1logo.jpg

 

NextPlat Reports 3Q Results with Nearly 35% Improvement in Year-Over-Year Gross Profit, Consolidated Quarterly Gross Margins of 35% & Approximately 66% Reduction in Net Loss

 

Company Sees 72% Growth in Higher Margin 340B Prescription Volumes as it Continues to Expand its Pharmacy Footprint

 

HALLANDALE BEACH, FL – November 12, 2026 – NextPlat Corp (NASDAQ: NXPL) (“NextPlat” or the “Company”), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced operating results for the third quarter ended September 30, 2026.

 

“Our third quarter results reflect continued year-over-year improvement across the business, driven by the refocusing of our healthcare operations on high-value, high-margin services designed to deliver consistent bottom-line results in what remains a dynamic market,” said David Phipps, Chief Executive Officer and President of NextPlat Corp. “Our focus remains on growth and profitability through our differentiated, high-value healthcare services and expanding community pharmacy network, including our new Scott’s location near Pensacola and a new pharmacy in Jacksonville, supported by a more efficient operating structure. Looking ahead, we anticipate further progress on our growth initiatives, including selective acquisitions, the introduction of new value-added services such as automated dispensing, and entry into new online healthcare and consumer markets

 

Third Quarter 2026 Financial Highlights:

 

● Consolidated revenue for the quarter ended September 30, 2026, was approximately $10.5 million versus $13.8 million reported in the third quarter of 2025. The change in revenue largely reflects lower reimbursement rates along with lower retail prescription volumes from our Healthcare operations. While these lower reimbursements reduce reported top-line revenue, they have contributed to a meaningful improvement in the Company’s gross margin. The Company expects retail prescription volumes to increase starting in the fourth quarter as it begins to recognize contributions from its recently acquired Pensacola area pharmacy and the opening of its new Jacksonville location.
     
  ○ Third quarter 2026 results reflected continued progress in the Company’s Healthcare operations as it works to expand its higher-value contracted pharmacy services offerings focused on supporting the needs of 340B, medication fulfillment facilities and other healthcare providers. Pharmacy contract revenue increased 300% to approximately $2.4 million compared with approximately $0.6 million in the prior-year period. The increase was attributable to growth in 340B contract revenue of approximately $1.6 million, which was driven by an increase in our existing 340B contracts of approximately $1.0 million and an increase in new 340B contract revenue of approximately $0.6 million, and an increase in medication fulfillment contract services of approximately $0.2 million. Pharmacy prescription revenue was approximately $4.3 million compared with approximately $9.5 million in the prior-year period. As anticipated, the year-over-year change mainly reflected lower reimbursement rates along and lower retail prescription volumes, factors that reduced top-line prescription revenue but helped strengthen segment gross margin. The strong growth in contracted 340B revenue partially offset the expected retail prescription reduction, demonstrating its potential to contribute more meaningfully in the coming quarters.
     
  ○ Third quarter 2026 e-commerce revenue increased 3% to approximately $3.8 million, compared with approximately $3.7 million in the third quarter of 2025, driven by record high-margin, recurring airtime contract revenue. Growth reflected continued strong global demand for satellite connectivity hardware and airtime services, with sales to customers in more than 115 countries during the quarter, and around 150 year-to-date. Sales through leading international e-commerce marketplaces remained strong. During the third quarter, the Company expanded its international sales channels through Decathlon, a leading international sporting-goods retailer, offering satellite connectivity products to online customers in 20 countries. The Company expects to attract additional new customers by launching on more international marketplaces during the fourth quarter and beyond.
     
● Overall gross margin for the third quarter ended September 30, 2026, remained near-record levels at approximately 35.0% compared to 19.9% recorded in 2025.
   
  ○ Gross margin in the Company’s Healthcare Operations segment continued to remain strong at approximately 41%, a 23 percentage point improvement from 18% recorded in the third quarter of 2025.
     
  ○ Gross margin in the Company’s e-Commerce Operations remained stable year-over-year during the third quarter of 2026 at approximately 24%.
   
● Total operating expenses for the quarter ended September 30, 2026 decreased to approximately $4.5 million from approximately $4.9 million in the prior year’s quarter primarily due to a decrease in salaries, wages and payroll taxes of approximately $0.3 million, a decrease in the loss on settlement of litigation of approximately $0.3 million, partially offset by the increase in professional fees of approximately $0.1 million.
   
● Net loss attributable to common stockholders for the quarter ended September 30, 2026 decreased approximately 66% to approximately $0.7 million or ($0.28) per diluted share, compared to a net loss attributable to common stockholders of approximately $2.2 million, or ($0.84) per diluted share for the three months ended September 30, 2025.
     
● The Company ended the quarter with approximately $11.2 million in cash, working capital of approximately $13.5 million, and no material unsecured debt as of September 30, 2026.

 

 

 

Organizational Highlights and Recent Business Developments:

 

● During the quarter, the Company’s Healthcare Operations saw continued growth in its higher-margin 340B contracted pharmacy services segment as prescription volumes grew nearly 72% year-over-year driven by the addition of multiple new entities secured since late last year. In the third quarter, the Company added three new 340B services contracts. Onboarding of these new customers is currently underway and is expected to contribute to increased revenue in early 2027.
   
● The Company continued to execute on its PharmcoRx pharmacy expansion plans, completing the profitable acquisition of Scott’s pharmacy in the Pensacola area of Northwest Florida immediately after the close of the quarter, and last month, announced the opening of its newest location in Jacksonville. Operating results of Scott’s Pharmacy remain strong as gross margins have improved and do not yet reflect the anticipated contributions from the launch of new high-value healthcare services for regional providers and patients which are currently underway. The Company continues to explore additional selective acquisitions that could significantly increase the scale of its pharmacy network, including those potentially beyond the state of Florida.
   
● E-commerce sales during the third quarter continued to reflect strong demand for satellite-based connectivity, in particular, revenue from airtime services, which reached a record high. The Company opened a new global consumer e-commerce sales channel through its UK subsidiary, Global Telesat Communications Ltd (GTC) in agreement with Decathlon, a leading international sporting-goods retailer which has begun selling an array of satellite connectivity products to its online customers in 20 countries.
   
● The Company is on track to launch its new nationwide medication fulfillment website during the fourth quarter following a comprehensive optimization of the platform to support e-commerce at scale. The new site will provide consumers across all 50 U.S. states with convenient online access to prescription and over-the-counter healthcare products and is expected to significantly expand PharmcoRx’s reach beyond Florida, establish a scalable national e-commerce sales channel, and support future healthcare revenue growth through broader consumer access and new partnership opportunities.

 

Third Quarter 2026 Conference Call Notification

 

NextPlat’s Chief Executive Officer and President, David Phipps, its Chief Financial Officer, Amanda Ferrio, and Vice President of Healthcare Operations, Birute Norkute, will host a conference call today, November 12th at 8:30 a.m. Eastern time to discuss the results for the quarter ended September 30, 2026, as well as other recent developments .

 

To access the call, please use the following information:

 

Date:

Thursday, November 12, 2026

Time:

8:30 a.m. Eastern time

Toll-free dial-in number:

1-877-407-9716

International dial-in number:

1-201-493-6779

Conference webcast link:

https://viavid.webcasts.com/starthere.jsp?ei=1782317&tp_key=5b15b90b68

 

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

 

The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1782317&tp_key=5b15b90b68  and via the investor relations section of the Company’s website at https://ir.nextplat.com/news-events/ir-calendar. A replay of the conference call will be available after 12:00 p.m. Eastern time through November 26, 2026 .

 

Toll-free replay number:

1-844-512-2921

International replay number:

1-412-317-6671

Replay entry code:

13763732

 

The financial information included in this press release should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to be filed with the Securities and Exchange Commission .

 

 

 

About NextPlat Corp

 

NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.

 

Forward-Looking Statements

 

Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company’s business and any of its products, services or solutions. The words “believe,” “forecast,” “project,” “intend,” “expect,” “plan,” “should,” “would,” and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company’s ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company’s previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

 

Media and Investor Contact for NextPlat Corp:

 

Michael Glickman

MWGCO, Inc.

917-397-2272

mike@mwgco.net

 

 

 

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except per share data)

(Unaudited)

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2026

   

2025

   

2026

   

2025

 

Revenues, net

  $ 10,499     $ 13,752     $ 32,235     $ 40,918  

Cost of revenue

    6,821       11,022       20,451       32,441  

Gross profit

    3,678       2,730       11,784       8,477  
                                 

Operating expenses:

                               

Selling, general and administrative

    2,032       1,899       6,483       5,924  

Salaries, wages and payroll taxes

    2,347       2,665       7,062       7,929  

Depreciation and amortization

    51       130       170       450  

Intangible asset amortization

    25       25       76       76  

Loss on settlement of litigation

    —       250       —       250  

Total operating expenses

    4,455       4,969       13,791       14,629  
                                 

Operating loss

    (777 )     (2,239 )     (2,007 )     (6,152 )

Non-operating (income) expense

    (9 )     (28 )     (11 )     (250 )

Loss before income taxes

    (768 )     (2,211 )     (1,996 )     (5,902 )

Income taxes benefit (expense)

    20       26       (28 )     (14 )

Net loss

    (748 )     (2,185 )     (2,024 )     (5,916 )

Net loss attributable to non-controlling interest

    —       —       14       —  

Net loss attributable to common stockholders

  $ (748 )   $ (2,185 )   $ (2,010 )   $ (5,916 )
                                 

Comprehensive loss:

                               

Net loss

  $ (748 )   $ (2,185 )   $ (2,024 )   $ (5,916 )

Foreign currency (loss) gain

    (5 )     18       12       (51 )

Comprehensive loss

  $ (753 )   $ (2,167 )   $ (2,012 )   $ (5,967 )
                                 

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

  $ (748 )   $ (2,185 )   $ (2,010 )   $ (5,916 )

Weighted average number of common shares outstanding – basic and diluted

    2,701       2,596       2,692       2,596  
                                 

Basic and diluted loss per share

  $ (0.28 )   $ (0.84 )   $ (0.75 )   $ (2.28 )

 

 

 

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except shares and par value data)

 

   

September 30, 2026

   

December 31, 2025

 
    (Unaudited)     (Audited)  

ASSETS

               

Current Assets

               

Cash

  $ 11,220     $ 13,709  

Receivables, net of allowances of $64 and $40 as of September 30, 2026 and December 31, 2025, respectively

    7,104       5,944  

Inventory, net of inventory reserves of $416 and $418 as of September 30, 2026 and December 31, 2025, respectively

    4,261       3,396  

Other current assets

    873       1,107  

Total Current Assets

    23,458       24,156  

Property and equipment, net of accumulated depreciation of $948 and $3,527 as of September 30, 2026 and December 31, 2025, respectively

    2,410       2,505  

Operating right-of-use assets, net

    691       189  

Goodwill

    156       156  

Intangible assets, net

    346       422  

Other noncurrent assets

    90       37  

Total Assets

  $ 27,151     $ 27,465  
                 

LIABILITIES AND EQUITY

               
                 

Current Liabilities

               

Accounts payable and accrued expenses

  $ 9,358     $ 8,265  

Notes payable

    122       416  

Operating lease liabilities

    179       158  

Other current liabilities

    340       287  

Total Current Liabilities

    9,999       9,126  
                 

Long Term Liabilities:

               

Notes payable, net of current portion

    810       876  

Operating lease liabilities, net of current portion

    501       41  

Total Liabilities

    11,310       10,043  
                 

Commitments and Contingencies

    —       —  
                 

Equity

               

Preferred stock ($0.0001 par value; 3,333,333 shares authorized; no shares issued or outstanding)

    —       —  

Common stock ($0.0001 par value; 50,000,000 shares authorized, 2,721,529 and 2,676,788 shares issued and 2,708,475 and 2,663,734 shares outstanding as of September 30, 2026 and December 31, 2025, respectively)

    —       3  

Additional paid-in capital

    78,020       77,586  

Accumulated deficit

    (62,073 )     (60,063 )

Accumulated other comprehensive loss

    (106 )     (118 )

Treasury stock (at cost; 13,054 shares as of September 30, 2026 and December 31, 2025)

    (100 )     (100 )

Equity attributable to common stockholders

    15,741       17,308  

Equity attributable to non-controlling interests

    100       114  

Total Equity

    15,841       17,422  
                 

Total Liabilities and Equity

  $ 27,151     $ 27,465  

   

 

Filing Exhibits & Attachments

5 documents

Keep reading